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Mammalian ribonucleases interact very strongly with
the intracellular ribonuclease inhibitor (RI). Eukaryotic
cells exposed to mammalian ribonucleases are protected
from their cytotoxic action by the intracellular inhibi-
tion of ribonucleases by RI. Human pancreatic ribonu-
clease (HPR) is structurally and functionally very simi-
lar to bovine RNase A and interacts with human RI with
a high affinity. In the current study, we have investi-
gated the involvement of Lys-7, Gln-11, Asn-71, Asn-88,
Gly-89, Ser-90, and Glu-111 in HPR in its interaction
with human ribonuclease inhibitor. These contact resi-
dues were mutated either individually or in combina-
tion to generate mutants K7A, Q11A, N71A, E111A, N88R,
G89R, S90R, K7A/E111A, Q11A/E111A, N71A/E111A, K7A/
N71A/E111A, Q11A/N71A/E111A, and K7A/Q11A/N71A/
E111A. Out of these, eight mutants, K7A, Q11A, N71A,
S90R, E111A, Q11A/E111A, N71A/E111A, and K7A/N71A/
E111A, showed an ability to evade RI more than the wild
type HPR, with the triple mutant K7A/N71A/E111A hav-
ing the maximum RI resistance. As a result, these vari-
ants exhibited higher cytotoxic activity than wild type
HPR. The mutation of Gly-89 in HPR produced no
change in the sensitivity of HPR for RI, whereas it has
been reported that mutating the equivalent residue
Gly-88 in RNase A yielded a variant with increased RI
resistance and cytotoxicity. Hence, despite its consider-
able homology with RNase A, HPR shows differences in
its interaction with RI. We demonstrate that interaction
between human pancreatic ribonuclease and RI can be
disrupted by mutating residues that are involved in
HPR-RI binding. The inhibitor-resistant cytotoxic HPR
mutants should be useful in developing therapeutic
molecules.
Mammalian ribonucleases constitute a ubiquitous superfam-
ily of proteins with a high level of structural and functional
divergence. These include a group of homologous proteins iso-
lated from many mammalian, avian, reptilian, and amphibian
sources and are collectively known to be part of the RNase A
superfamily (1). The current resurgence of interest in RNases
is the result of the discovery of RISBASES (RNases with Spe-
cial Biological Actions), which have been identified to influence
tumor cell growth, neurological development, and biological
differentiation (2). An important biological function of mamma-
lian RNases may be host defense, as has been observed in the
case of the two eosinophil RNases, eosinophil cationic protein
and eosinophil-derived neurotoxin, which exhibit antiviral, an-
tibacterial, antiparasitic, and neurotoxic activities (3–7). Also,
frog RNase onconase and bovine seminal ribonuclease (BS-
RNase)1 exhibit antitumor activity (8–11).
Human pancreatic ribonuclease (HPR) is secretory in nature
and has been considered as a counterpart of bovine pancreatic
RNase A (12, 13). Although HPR shares 70% homology with
RNase A and possesses similar key structural and catalytic
residues, it displays some unique features (14). HPR possesses
substantial activity against double-stranded RNA, contains a
higher proportion of basic residues, its activity is differentially
influenced by ionic strength and divalent ions, and compared
with RNase A it has a carboxyl-terminal extension of four
residues, EDST (15–17). We have reported earlier that deletion
of the carboxyl-terminal EDST extension enhances the RNase
activity and thermostability of HPR (18). Although both RNase
A and HPR catalyze RNA degradation efficiently, they have not
been associated with any special biological action, and hence
their physiological role, especially that of HPR, is not clearly
defined. RNases have much potential as chemotherapeutics.
Onconase is presently undergoing phase III human clinical
trials for the treatment of malignant mesothelemia (19) and
has also been shown to inhibit human immunodeficiency virus
type I replication in chronically infected human cells (20). A
majority of pancreatic RNases, with the exception of BS-RNase
and onconase, are not cytotoxic. The major apparent reason for
this poor cytotoxicity is the neutralization of the ribonucleolytic
activity of RNases by the cytosolic RNase inhibitor (RI). Hence,
affinity of a RNase for the intracellular RI could play an im-
portant role in defining its cytotoxic potency. HPR holds tre-
mendous promise as a therapeutic agent for humans, and com-
pared with other RNases it is likely to be less immunogenic and
thus more efficacious. When the RI-sensitive “noncytotoxic”
RNases are injected directly into Xenopus oocytes, which lack
strong inhibitors to mammalian RNases, they display cytotoxic
activity comparable to ricin and diphtheria toxin (21). More-
over, the two classes of RNases with anticancer activity, onco-
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nase and BS-RNase, are found to be resistant to cytosolic RI
protein, and their cytotoxic activities appear to be a conse-
quence of their abilities to escape inactivation by RI. (22, 23).
BS-RNase is a naturally occurring homodimer that is stabilized
by two intersubunit disulfide bridges. The BS-RNase monomer
is highly homologous to RNase A; however, the dimeric form
has a much lower affinity for RI than the free monomer (23).
Onconase evades RI as a monomer because of a lack of amino
acid residues that are responsible for making contact with RI.
Only three residues that contact RI in RNase A are conserved
in onconase (19, 24). RI is a 50-kDa protein that constitutes
0.01% of the total cytosolic protein and is a highly conserved
protein in various mammalian species (25, 26). RI forms a 1:1
noncovalent complex with RNase A; and as seen from the
three-dimensional structure of pRIzRNase A complex, one-third
of the enzyme, including its active site, sits within the horse-
shoe-shaped structure of the inhibitor (27). A similar interac-
tion has been observed with angiogenin and human RI (hRI);
however, the intermolecular contacts in the RIzRNase complex
differ because of the differences in the sequences of the two
RNases (28). Recently, the crystal structure of a variant of
HPR, having five amino-terminal residues replaced by those in
the BS-RNase, has been determined (29). The structure of this
HPR variant shares the overall size and characteristic V shape
of the other RNases of its family; however, it differs signifi-
cantly from RNase A in various loop regions (29).
It has been demonstrated recently that RNase A can be
engineered as a cytotoxin by mutating the specific contact
residue Gly-88, which led to a decrease in its susceptibility to
RI inactivation (30). Because the potency of a cytotoxic RNase
can be defined in terms of its affinity for the RI, it is possible
that HPR could be transformed into a cytotoxin by lowering its
sensitivity to RI inactivation. In the current study we have
investigated the role of four plausible contact residues in HPR
in its interaction with the hRI with an aim to generate cytotoxic
HPR variants. We have generated variants of HPR which have
enhanced resistance toward inactivation by the hRI and are
more cytotoxic.
EXPERIMENTAL PROCEDURES
Construction of HPR Mutants—HPR is a protein consisting of 128
amino acid residues. pHPR, a plasmid containing the 384- base pair
HPR gene, cloned downstream of a T7 promoter (18), was used as
template to mutate the target residues Lys-7, Gln-11, Asn-71, and
Glu-111 to Ala. Similarly, the residues Asn-88, Gly-89, and Ser-90 were
mutated to arginine. Except for K7A, all of the mutations were carried
out by oligonucleotide-mediated site-directed mutagenesis (31). Uracil
containing DNA template was prepared by infecting CJ236 strain of
Escherichia coli with the recombinant phage and growing it in the
presence of uridine and chloramphenicol (31). Mutagenesis was per-
formed using DNA primers JKB 8, JKB 9, JKB 10, JKB 11, JKB 15,
JKB 16, and JKB 29 containing the mutations G89R, N88R, K7A,
Q11A, N71A, E111A, and S90R, respectively. Sequences of various
primers used are shown in Table I. Primer extension products were
FIG. 1. SDS-polyacrylamide gel electrophoresis and Western
blot analysis of HPR mutants. The mutants were expressed in
BL21(lDE3) cells of E. coli and purified from the inclusion bodies by
cation exchange and gel filtration chromatography. The recombinant
proteins were analyzed by 12.5% SDS-polyacrylamide gel electrophore-
sis under reducing conditions followed by Coomassie Blue staining
(panel A). Western blot analysis of the mutants was done using a
polyclonal antibody raised against HPR (panel B). The different lanes in
panel B correspond to the same proteins in panel A.
FIG. 2. CD spectral analysis of HPR and its mutants. CD spectra
were recorded in far UV region (200–250 nm) at 25 °C. The spectra are
presented as mean residue ellipticity, expressed in degreeszcm2/dmol 3
1023. Panel A, HPR (——), K7A (– – –), Q11A (– z – z –), N71A (- z - z -),
and E111A (- - - - -). Panel B, HPR (——), Q11A/E111A (- - - - -),
K7A/E111A (– z – z –), and N71A/E111A (– – –). Panel C, HPR (——),
K7A/N71A/E111A (- - - - -), Q11A/N71A/E111A (– – –), and K7A/Q11A/
N71A/E111A (– z – z –). Panel D, HPR (——), N88R (- z - z -), G89R (z z z
z z), and S90R (– z – z –).
TABLE I
Sequence of primers used for mutagenesis of the putative residues
The underlined letters in lower case represent the nucleotides mutated.
Mutant Primer Sequence
K7A JKB 10 59-ATGGCTAGCAAGGAATCCCGGGCCAAGgctTTCCAGCGG-39
Q11A JKB 11 59-ACTGTCTGAGTCCATATGagcCCGCTGGAATTTCTTGGC-39
N71A JKB 15 59-GGAGTTGCTCTTGTAGCAagcGCCCTGCCCGTTCTTGCA-39
E111A JKB 16 59-TGGCACATATGGGCTCCCagcACAGGCCACAATGATGTG-39
N88R JKB 9 59-GTTGGGGTACCTGGAGCCcctTGTCAGGCGGCAGTCTGT-39
G89R JKB 8 59-ACAGTTGGGGTACCTGGAcctGTTTGTCAGGCGGCAGTC-39
S90R JKB 29 59-TGCACAGTTGGGGTAcctACGGCCGTTTGTCAGGCGGCA-39
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transformed into E. coli strain DH5a by standard methods. The mutant
K7A was constructed by polymerase chain reaction using pHPR as the
template, JKB 10 as the forward primer, and a universal EcoRI reverse
primer. The primers were designed such that the amplified HPR frag-
ment carrying the mutation K7A had recognition sites for NheI at the
59-end and EcoRI at the 39-end. The amplified fragment was digested
with NheI and EcoRI, purified by gel electrophoresis, and cloned into a
T7 promoter based-E. coli expression vector pVEX11 restricted with the
same enzymes. pVEX11 is a pUC-based vector that has a phage T7
promoter, multiple cloning sites, and a T7 transcription terminator.
For constructing the double mutants K7A/E111A, Q11A/E111A, and
N71A/E111A, mutants K7A, Q11A, N71A, and E111A were digested
with NheI (present at the 59-end) and KpnI (present at position 292 in
the HPR gene), and the 290-base pair fragment released from the
mutants was ligated with the NheI-KpnI vector fragment obtained from
the E111A mutant. The triple mutant K7A/N71A/E111A was prepared
by mutating the Lys-7 to Ala by polymerase chain reaction as men-
tioned above, using the double mutant N71A/E111A as the template.
The triple mutant Q11A/N71A/E111A was created by oligonucleotide-
mediated site-directed mutagenesis using the double mutant N71A/
E111A as the template and primer JKB 11. For the construction of the
quadruple mutant K7A/Q11A/N71A/ E111A, the triple mutant Q11A/
N71A/E111A was used as the template, and the K7A mutation was
introduced by polymerase chain reaction. All mutations were confirmed
by DNA sequencing using the dideoxy chain termination method (32).
Expression and Purification of the Recombinant Proteins—HPR has
been overexpressed earlier in E. coli and purified from the inclusion
bodies to obtain functionally active enzyme (18). The HPR mutant
proteins were prepared similarly from the cultures of E. coli strain
BL21(lDE3), transformed with appropriate plasmid, and grown in su-
perbroth containing 100 mg/ml ampicillin (18). All HPR mutants were
found to accumulate in cytoplasmic inclusion bodies that were pro-
cessed further as described (33). The solubilization of the inclusion body
pellet was achieved in 6 M guanidium HCl. Renaturation of the solubi-
lized protein was done by diluting the protein in a refolding buffer
containing L-arginine and oxidized glutathione. The renatured protein,
after dialysis, was loaded on an S-Sepharose cation exchange column.
The protein was eluted with a gradient of 0–1 M NaCl and purified
further by gel filtration chromatography (18).
Structural Characterization by Circular Dichroism—CD-spectra of
purified proteins were recorded using a Jasco J720 (Easton) dichro-
graph in the far UV region (190–250 nm). Each protein, 33 mg/ml in 10
mM sodium phosphate, pH 7.0, was used in a cell with a 1-cm optical
path to record the spectra. The spectra were acquired at a scan speed of
50 nm/min with a sensitivity of 50 mdeg and response time of 1 s. The
spectra measured were an average of 10 accumulations, and the results
are presented as mean residual ellipticity values.
Assay of Ribonucleolytic Activity of HPR and Mutants—The ribonu-
cleolytic activity of various mutants was assayed on substrates poly(C),
poly(U), yeast tRNA, and poly(AzU) as described by Bond (34). Each
substrate (40 mg) was incubated separately with different concentra-
tions of the wild type HPR or its mutants in 100 mM Tris-HCl, pH 7.5,
for 1 h at 37 °C. The undigested large molecular weight RNA was
precipitated with perchloric acid and uranyl acetate on ice and removed
by centrifugation at 15,000 3 g for 10 min. The acid-soluble product was
quantitated by measuring the absorbance at 260 nm.
The hydrolytic activity of HPR and its mutants on cyclic CMP was
assayed according to the method of Crook et al. (35). In a reaction buffer
consisting of 0.2 M Tris-HCl, pH 7.5, and 0.02 M EDTA, 0.1 mg/ml cyclic
CMP was mixed with 40 mg/ml of the enzyme, and the reaction was
monitored spectrophotometrically at 284 nm at 25 °C.
The RNase activity of various proteins on dinucleotide substrates
CpA, UpA, and UpG was measured by using the procedure of Witzel
and Barnard (36). The appropriate substrate, 50 mM in 100 mM Tris-HCl
buffer, pH 7.0, was incubated with HPR or its mutants (final concen-
tration 5 mM) at 25 °C. The change in absorbance at 284 nm was
monitored spectrophotometrically.
RI Binding Assays—The HPR mutants were screened for ribonucleo-
lytic activity in the presence of hRI by using an agarose gel-based assay
(30). Briefly, in a total volume of 10 ml, 10 ng of enzyme was mixed with
4 mg of total rat liver RNA and 20 units of recombinant hRI in 100 mM
Tris-HCl, pH 7.5, containing10 mM dithiothreitol. The mixture was
incubated for 10 min at 37 °C; the reaction was stopped by the addition
of 2 ml of gel loading buffer containing 10 mM Tris-HCl, pH 7.5, 50 mM
EDTA, glycerol (30% v/v), xylene cyanol FF (0.25% w/v), and bromphe-
nol blue (0.25% w/v) and subjected to electrophoresis on a 1.5% agarose
gel containing ethidium bromide.
The RNase activity of the mutants, in the presence of RI, was studied
quantitatively by assaying their activity on the most preferred RNA
homopolymer substrate, poly(C), in an assay described above (34).
The inhibition constants (Ki) for the RI-HPR mutant interactions
were determined by measuring the steady-state rate of poly(C) cleavage
in the presence of RI. Reactions were performed in 100 mM Tris-HCl, pH
7.5, containing 2.8 nM enzyme and 50–300 mM poly(C). RI concentra-
tions in the range 300–700 pM were used, and the initial velocity data
were used to prepare Lineweaver-Burk plots, from which Ki was
calculated.
Cytotoxicity Assays—The cytotoxicity assays were performed on five
different cell lines: U373MG (human glioblastoma), J774A.1 (mouse
monocyte-macrophage), K562 (human erythroleukemia), A431 (human
epidermoid carcinoma), and A549 (human lung carcinoma). Cytotoxic-
ity was evaluated by measuring [3H]leucine incorporation into newly
synthesized protein. Cells were incubated with RNases for 40 h, fol-
lowed by a 3-h pulse with 0.75 mCi/well [3H]leucine. The cells were then
harvested onto glass fiber filters using a cell harvester. The filters were
dried, and counts were taken using a liquid scintillation counter. The
ID50 values represent the concentration of the RNase which inhibited
the cellular protein synthesis by 50%.
TABLE II
Catalytic activity of HPR mutants
Substrates poly(C), yeast tRNA, and cCMP were incubated separately with different concentrations of the wild type HPR or its mutants for 1 h
at 37 °C. The undigested large molecular weight RNA was precipitated with perchloric acid and uranyl acetate on ice and removed by
centrifugation. The acid-soluble product was quantitated by measuring the absorbance at 260 nm. Each dinucleotide substrate was incubated with
HPR and its mutants at 25 °C. The change in absorbance at 284 nm was monitored spectrophotometrically. The specific activity has been expressed
as DA/min/mg protein. The percent activity compared with the HPR activity is shown in parentheses. ND, not determinable.
Protein
DA/min/mg protein
Poly(C) Yeast tRNA cCMP CpA UpA UpG
HPR 227,000 (100) 16,300 (100) 0.37 (100) 0.140 0.138 ND
K7A 241,000 (106) 12,800 (78) 0.45 (121) 0.148 0.130 ND
Q11A 186,000 (82) 7,950 (48) 0.29 (78) 0.130 0.020 ND
N71A 313,000 (140) 7,600 (46) 0.67 (181) 0.120 0.050 0.280
E111A 508,000 (224) 8,800 (53) 0.54 (145) 0.130 0.077 0.070
TABLE III
Catalytic activity of the HPR mutants on poly(C)
The poly(C) substrate was incubated with different concentrations of
the wild type HPR and its mutants for 1 h at 37 °C. The undigested
large molecular weight RNA was precipitated with perchloric acid and
uranyl acetate on ice and removed by centrifugation. The acid-soluble
product was quantitated by measuring the absorbance at 260 nm. The
specific activity has been expressed as DA/min/mg protein. The percent
activity compared with the HPR activity is shown in parentheses.
Protein DA/min/mg protein
HPR 227,000 (100)
K7A/E111A 292,000 (128)
Q11A/E111A 80,000 (35)
N71A/E111A 688,000 (303)
K7A/N71A/E111A 262,000 (115)
Q11A/N71A/E111A 48,000 (21)
K7A/Q11A/N71A/E111A 48,000 (21)
N88R 237,000 (104)
G89R 220,000 (97)
S90R 232,500 (102)
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RESULTS
Design of HPR Mutants
The aim of the study was to investigate whether the affinity
of HPR for RI could be reduced by mutating specific contact
residues, presumably involved in the binding of HPR to RI. We
selected target residues in HPR based on two criteria. First, the
residue must be involved in binding of HPR with RI by either
forming a hydrogen bond or van der Waal contact with RI, as
defined by the crystal structure of the RIzRNase complex. Sec-
ond, the target residue must not be involved in the active site
of HPR.
On the basis of homology studies with the residues involved
in the RI binding of several RNases, especially RNase A, we
selected four target residues in HPR: Lys-7, Gln-11, Asn-71,
and Glu-111. We replaced these residues in HPR with alanine
to yield mutants K7A, Q11A, N71A, and E111A. Alanine was
chosen because it eliminates the side chain beyond the b-car-
bon without altering the main conformation. We combined the
single mutations to form three double mutants, K7A/E111A,
Q11A/E111A, and N71A/E111A; two triple mutants, K7A/
N71A/E111A and Q11A/N71A/E111A; and a quadruplet mu-
tant, K7A/Q11A/N71A/E111A.
In RNase A mutation of Gly-88 to Arg has been shown to
decrease its sensitivity to RI inactivation and consequently
increase the cytotoxic potency by many fold (30). Gly-88 in
RNase A is homologous to Gly-89 in HPR. In the current study
we individually mutated Gly-89 and also Asn-88 and Ser-90 to
Arg, yielding three single mutants, N88R, G89R, and S90R.
Expression and Purification of HPR Mutants
The mutants were expressed in E. coli, and the overex-
pressed proteins, isolated from the inclusion bodies, were pu-
rified to homogeneity through a two-step purification scheme
comprised of cation exchange and gel filtration chromatogra-
phy. The purified HPR mutants migrated on SDS-polyacryl-
amide gel electrophoresis as single bands corresponding to
their expected molecular weights (Fig. 1A). A polyclonal anti-
body against HPR reacted with all 13 mutant proteins equally
well as shown by the Western blots (Fig. 1B). Typical final
yields of the purified recombinant proteins were in the range of
10–20 mg/liter of culture.
Structural Characterization of the Proteins by Circular
Dichroism
Structural characterization was carried out by CD spectral
analysis to study the effect of mutations on the overall confor-
mation of HPR. As shown in Fig. 2, the recombinant HPR
appears to be folded compactly with an a1b conformation. The
CD spectra of the mutant proteins K7A, Q11A, N71A, and
E111A (Fig. 2A); K7A/E111A, Q11A/E111A, and N71A/E111A
(Fig. 2B); K7A/N71A/E111A, Q11A/N71A/E111A, and K7A/
Q11A/N71A/E111A (Fig. 2C); and N88R and G89R (Fig. 2D)
indicated a modest alteration; however, the overall structure
appears to be similar to that of the wild type protein. The
conformation of S90R (Fig. 2D) was found to be altered com-
pared with the wild type HPR, showing a significant decrease
in the a-helical content of the mutant.
Enzymatic Activity of HPR and Its Mutants
The RNase activity of the seven single alanine mutants was
assayed on three different RNA substrates: poly(C), yeast
tRNA, and cyclic CMP. Pancreatic RNases have a preference
for pyrimidine-rich RNA substrates. On the single-stranded,
pyrimidine homopolymer substrate, poly(C), the mutants K7A,
Q11A, N71A, and E111A displayed a similar or higher activity
compared with wild type HPR (Table II). On yeast tRNA, the
mutant K7A showed 78% activity compared with the wild type
enzyme, whereas the mutants Q11A, N71A, and E111A dis-
played about 50% lower activity (Table II). The hydrolytic
activity of HPR and its mutants was studied by spectrophoto-
metrically monitoring the breakdown of the cyclic CMP to
39-monophosphate. The mutants K7A, Q11A, N71A, and
FIG. 3. Agarose gel-based assay of
HPR inhibition by RI. The extent of RI
inactivation of HPR and its mutants was
analyzed by visualizing the RNase-cata-
lyzed degradation of the 28 S and 18 S
rRNA in the presence and absence of RI
(20 units/rxn). Panel A, effect of RI on the
activity of HPR and single mutants K7A,
Q11A, N71A, and E111A. Panel B, RNase
activity of K7A/N71A/E111A, N71A/
E111A, and Q11A/E111A and the argi-
nine mutants N88R, G89R, and S90R in
the absence and presence of RI.
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E111A were found to possess hydrolytic activity similar to that
of the wild type HPR (Table II).
The mutants K7A, Q11A, N71A, and E111A exhibited activ-
ity similar to the wild type enzyme on the most favored dinu-
cleotide substrate CpA (Table II). On UpA, the mutant K7A
showed activity similar to that of HPR, but there was a signif-
icant loss in activity of the mutants Q11A, N71A, and E111A
(Table II). On the dinucleotide substrate UpG, like HPR, mu-
tants K7A and Q11A also were found to be inactive, whereas
mutants N71A and E111A displayed RNase activity, with
N71A being more active (Table II).
On poly(C), compared with HPR the mutant N71A/E111A
was found to have a 3-fold higher activity (Table III). The
activity of the mutants N88R, G89R, S90R, K7A/E111A, and
K7A/N71A/E111A was found to be similar to that of the wild
type HPR on poly(C), whereas the mutants Q11A/E111A,
Q11A/N71A/E111A, and K7A/Q11A/N71A/E111A displayed
very poor RNase activity (Table III).
Interaction of HPR Mutants with RI
Agarose Gel-based Assay—The agarose gel-based assay is a
visual qualitative assay in which the extent of RNA degrada-
tion observed in the gel is an indication of the effect of RI on
HPR activity. In the absence of RI, a progressive increase in
total rat liver RNA degradation was observed with increasing
amount of HPR (Fig. 3A). The RNase shows a preference for the
28 S rRNA. The mutants K7A, Q11A, N71A, and E111A also
displayed RNase activity similar to wild type HPR (Fig. 3A). In
the presence of RI (20 units), the activity of HPR was signifi-
cantly inhibited, indicating its high sensitivity to RI (Fig. 3A).
The single alanine mutants, however, were able to degrade the
RNA substrate even in the presence of RI at all enzyme con-
centrations used, except at a very low concentration of 0.1 ng,
implying a decreased inhibitory effect of RI on these mutants
(Fig. 3A).
The double mutants Q11A/E111A and N71A/E111A and the
triple mutant K7A/N71A/E111A also showed a higher resist-
ance to RI, and they were able to degrade rRNA to a greater
extent than HPR in the presence of inhibitor (Fig. 3B). Because
the mutant N71A/E111A was enzymatically 2.5-fold more ac-
tive, and Q11A/E111A 3-fold less active, in the agarose gel-
based assay 2.5 times lower amount of N71A/E111A and 3
times higher amounts of Q11A/E111A were also included to
equalize their enzymatic activity with HPR (Fig. 3B).
The extent of RNA degradation observed with N88R, G89R,
and S90R in the absence or presence of RI was similar to that
observed for HPR, implying that these residues are not crucial
for HPR-RI binding (Fig. 3B).
Assay of Enzymatic Activity of the Mutants in the Presence of
RI—The RNase activity of the mutants, in the presence of RI,
was quantitated by assaying their activity on the most pre-
ferred RNA homopolymer substrate, poly(C) (Fig. 4). For these
studies mutants K7A, Q11A, N71A, E111A, Q11A/E111A,
N71A/E111A, and K7A/N71A/E111A displaying greater resist-
ance to RI were taken. As shown in Fig. 4A, at a fixed enzyme
concentration of 0.8 ng and RI concentration of 0.25 unit, HPR,
K7A, and N71A showed 30% activity, whereas the mutants
Q11A and E111A exhibited 60–80% activity. However, when
the enzyme concentration was increased to 1.6 ng, all the four
mutants showed 100% activity even in the presence of 0.25 unit
of RI, whereas HPR exhibited only 50% activity (Fig. 4B).
These results demonstrate that the four mutants K7A, Q11A,
N71A, and E111A are less sensitive to RI than HPR, and
among these the mutants Q11A and E111A appear to be more
resistant to RI than K7A and N71A (Fig. 4A).
Similarly, the mutants Q11A/E111A, N71A/E111A, and
K7A/N71A/E111A exhibited 65–95% activity at an enzyme con-
centration of 0.8 ng and RI concentration of 0.25 unit/rxn,
whereas wild type HPR showed only 30% activity (Fig. 4C). On
further increasing the RI concentration to 0.5 unit/rxn, the
three mutants still showed 50–70% activity compared with
only 10% of HPR (Fig. 4D).
Inhibition Constants—The inhibition constants (Ki) for the
RI-HPR mutant interactions were determined by measuring
the steady-state rate of poly(C) cleavage in the presence of RI.
FIG. 4. RNase activity of HPR mutants on poly(C) in the pres-
ence of RI. The activity of the HPR mutants on the most favored RNA
substrate poly(C) in the presence of RI was measured and has been
plotted in terms of percent activity compared with the RNase activity of
the proteins in the absence of RI. The values presented are means with
S.E. from four independent experiments. Panel A, activity of mutants
K7A, Q11A, N71A, and E111A; 0.8 ng of enzyme and 0.25 unit of RI.
Panel B, activity of mutants K7A, Q11A, N71A, and E111A; 1.6 ng of
enzyme and 0.25 unit of RI. Panel C, activity of mutants Q11A/E111A,
N71A/E111A, and K7A/N71A/E111A; 0.8 ng of enzyme and 0.25 unit of
RI. Panel D, activity of mutants Q11A/E111A, N71A/E111A, and K7A/
N71A/E111A; 0.8 ng of enzyme and 0.50 unit of RI.
TABLE IV
Inhibition constant (Ki) values for RI interaction of HPR and its
mutants
The inhibition constants (Ki) were determined by measuring the
steady-state rate of poly(C) cleavage in the presence of RI. Respective
enzymes were incubated with different concentrations of the RNA sub-
strate poly(C) and RI. Initial velocity data were used to prepare Lin-
eweaver-Burk plots, from which the Ki was calculated.
Protein Ki
pM
HPR 20
K7A 166
Q11A 233
N71A 100
E111A 366
Q11A/E111A 212
N71A/E111A 364
K7A/N71A/E111A 500
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Initial velocity data were used to prepare Lineweaver-Burk
plots, from which Ki was calculated. As shown in Table IV, the
Ki values for the mutants were significantly higher than that of
HPR. The Ki value of the triple mutant K7A/N71A/E111A was
25-fold higher than that of HPR, followed by the mutants
N71A/E111A and E111A, which had an 18-fold higher value.
Both Q11A and Q11A/E111A had a 10-fold higher Ki value than
HPR, whereas those for K7A and N71A were 8- and 5-fold
higher, respectively.
Cytotoxic Activity of HPR Mutants
To study the effect of mutations on the interaction of HPR
with the intracellular RI, cytotoxic activity of HPR and its
mutants was assayed on five different cell lines, U373MG,
J774.A1, K562, A431, and A549. All mutants except Q11A/
N71A/E111A, N88R, and G89R displayed a higher cytotoxic
activity than the wild type HPR, as depicted in their lower ID50
values (Table V). The mutants K7A/N71A/E111A, E111A, and
Q11A displayed the maximum cytotoxic activity. Out of the five
cell lines used in the study, U373MG and J774A.1 were the
most sensitive to these mutants. The triple mutant K7A/N71A/
E111A was found to be the most potent. It exhibited at least a
10-fold higher cytotoxic activity compared with HPR on
U373MG cell line, a 4-fold higher activity on J774A.1, and
2–3-fold higher activity on K562, A431, and A549. Similarly,
the cytotoxic activity of the mutants E111A and Q11A varied
from at least 2- to 3-fold more than that of HPR (Table V). The
mutants N71A/E111A, Q11A/E111A, K7A, N71A, and S90R
were found not to be as potent; however, they exhibited up to a
2-fold higher cytotoxic activity than HPR depending on the cell
line. The mutants Q11A/N71A/E111A, N88R, and G89R
showed cytotoxic activity similar to that of HPR on all cell lines
studied (Table V).
DISCUSSION
An important prerequisite for a RNase to act as a cytotoxic
molecule is its ability to escape inactivation by RI, present in
the cytosol of mammalian cells, which functions to preserve the
integrity of cellular RNA (22, 25, 37). Onconase, although a
much weaker RNase than RNase A, is highly cytotoxic because
it evades RI exceptionally well (19, 24). In RNase A replacing
Gly-88 with arginine or aspartic acid has been shown to result
in 103-104 fold higher resistance to hRI, and the mutants ex-
hibit a potent toxic effect on K562 cells (30).
In this study, with an aim to investigate the HPR-hRI inter-
action and to generate a cytotoxic HPR mutant(s), we have
mutated, either individually or in combination, seven residues
in HPR which are presumably involved in its interaction with
RI. The individual mutations of the four residues Lys-7, Gln-
11, Asn-71, and Glu-111 were not detrimental to the activity of
HPR on poly(C); however, these mutants had reduced activity
on yeast tRNA. These residues appear to be involved in sub-
strate binding in HPR, similar to that in RNase A. In RNase A,
Lys-7 is present in the phosphate binding subsite (38–41),
whereas Asn-71 and Glu-111 are present in the base binding
subsite (41–43). The primary role of Gln-11, a conserved resi-
due that donates a hydrogen bond to the reactive phosphoryl
group of the bound substrate, is to prevent the nonproductive
binding of the substrate (44). Using dinucleotide monophos-
phates as substrates, Witzel and Barnard (36) showed that the
rate constant of RNase A is higher when the base at 59 position
is a purine, the order being A . G . C . U (36). The mutations
N71A and E111A produced a change in the substrate specificity
of HPR. The four individual mutations were combined further
to prepare mutants K7A/E111A, Q11A/E111A, N71A/E111A,
K7A/N71A/E111A, Q11A/N71A/E111A, and K7A/Q11A/N71A/
E111A. However, only K7A/E111A, N71A/E111A, and K7A/
N71A/E111A had full enzymatic activity. An interesting infer-
ence from these inactive mutants is that the presence of either
Gln-11 or Glu-111 in HPR appears to be absolutely essential for
the full ribonucleolytic activity of the enzyme, and simultane-
ous mutation of both these residues is detrimental to the ac-
tivity of HPR.
The mutation of Lys-7, Gln-11, Asn-71, and Glu-111 to Ala
resulted in a decrease in the sensitivity of HPR to RI inactiva-
tion. There was a further augmentation in resistance to RI on
combining these individual mutations, as seen in the case of
the active double mutant N71A/E111A and triple mutant K7A/
N71A/E111A. The triple mutant K7A/N71A/E111A showing
the maximum RI resistance had a Ki value 25-fold greater than
that of HPR. The greater ability of the mutants to escape RI
inactivation was also reflected in their improved cytotoxic ac-
tivity on a variety of cell lines. The triple mutant K7A/N71A/
E111A was found to be most potent, displaying a minimum
10-fold higher cell killing ability than HPR on the glioma cell
line U373MG. The double mutant Q11A/E111A, despite being
60% less active than HPR, was found to be almost 2-fold more
cytotoxic than the wild type enzyme. The 10-fold higher RI
resistance of the double mutant Q11A/E111A, compared with
HPR, appears to be responsible for its enhanced cytotoxic ac-
tivity. A similar result was observed in RNase A by Bretscher
et al. (45). They found a double mutant K41R/G88R of RNase A
to be enzymatically less active than the single G88R mutant
but more cytotoxic. The double mutant showed a very low
affinity for RI, which apparently accounts for the enhanced
TABLE V
Cytotoxicity of HPR mutants on various cell line
Cytotoxicity was evaluated by measuring [3H]leucine incorporation into newly synthesized protein. Results from the cytotoxicity assays are
expressed in the form of ID50 values. The ID50 values represent the concentration of the ribonuclease producing a 50% inhibition of cellular protein
synthesis.
Protein
ID50
U373MG J774A.1 K562 A431 A549
mg/ml
HPR .200 80 150 160 .200
K7A 120 46 75 62 150
Q11A 98 41 55 60 84
N71A 155 57 75 62 84
E111A 84 26 54 49 40
Q11A/E111A .160 42 105 80 .160
N71A/E111A 150 52 80 75 150
K7A/N71A/E111A 20 18 80 57 80
Q11A/N71A/E111A .200 68 160 .200 .200
N88R .200 80 .200 .200 .200
G89R .200 70 .200 175 .200
S90R 145 38 100 125 120
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cytotoxicity. In contrast, another double mutant K41A/G88R of
RNase A, which has the same affinity for RI but is a much
weaker RNase compared with K41R/G88R mutant, is not cyto-
toxic. These data suggest that for a variant of RNase A to be
cytotoxic, it is necessary to maintain sufficient ribonucleolytic
activity (45). In the current study equivalent mutations in HPR
did not produce similar results, and the mutations of Asn-88
and Gly-89 to Arg had no effect on the interaction of HPR with
RI. Only the mutant S90R displayed a higher cytotoxicity than
HPR. Pous et al. (29) have also reported similar results with a
N88R/G89R double mutant of HPR. Our study clearly demon-
strates that even though RNase A and HPR share a very close
homology, with the key structural and catalytic residues iden-
tified in the bovine analog retained in the human enzyme, the
observations with RNase A cannot be fully extended in HPR.
Recently the crystal structure of a variant of HPR has been
determined (29). The variant has 5 residues in the first 20
residues in its amino terminus replaced by the equivalent
residues in the BS-RNase. The structure exhibits three helices
(a, a2, and a3) and seven b strands (b1–b7). Strand b1 is
positioned between the helices a2 and a3, and the rest of the
strands are located in sequence after a3. Strands b31b4 and
b51b6 run antiparallel and form a twisted b sheet defining the
V-shaped cleft where the active site is located. The core struc-
ture of the HPR variant is very similar to that of RNase A;
however, it differs in the loop regions. The active site cleft
shows an architecture similar to that of RNase A with essential
amino acids occupying the equivalent positions. However, re-
markable differences are found at loops b4b5 (residues 90 and
91), and a2b1 (residues 37 and 38). The loop b2b3 in the HPR
variant also has a different conformation compared with that in
RNase A (residue 67). From the three-dimensional structure of
pRIzRNase A and angiogeninzhRI complexes it is apparent that
the contact surface mainly involves a2b1, b2b3, and b4b5 in
RNase A and loops a2b1 and b4b5 in angiogenin, apart from
the residues belonging to their respective active sites (24, 27,
28). The loop comprising amino acids 87–89 has been shown to
be highly exposed in HPR structure with a different conforma-
tion; accordingly, it is proposed that regions a2b1 (residues
33–43) and b2b3 (residues 64–71) might be involved signifi-
cantly in the interaction of HPR with RI (29). Our results also
support this proposal as we have observed an increased resist-
ance in HPR variants containing Asn-71 mutation, which lies
in the b2b3 region. Based on the crystal structures of the
RIzRNase A complex and hot spot mutagenesis in hRI, residues
Lys-7 and Gln-11 of RNase A interact with Ser-460; Asn-71
with Tyr-437; and Glu-111 with Tyr-437, Trp-438, Ser-439, and
Glu-460 of the inhibitor (46–48). In this study with HPR we
also observed increased resistance in HPR mutants where
these residues were mutated.
In conclusion, we have demonstrated that residues Lys-7,
Gln-11, Asn-71 and Glu-111 in HPR are involved in its inter-
action with the hRI, and mutants with these residues replaced
by alanine have higher resistance toward inactivation by RI.
Further investigation of contact residues might prove useful in
developing much more potent cytotoxic variants of HPR.
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